seborrhea treatment - Health Topics
Please provide your email address to receive an email when new articles are posted on . On Dec. 16, 2023, roflumilast foam 0.3% was FDA-approved for the treatment of seborrheic dermatitis.
Understanding the Context
The results ... Nasdaq: CORRECTION: Nationwide Survey of People with Seborrheic Dermatitis Reveals Dissatisfaction with Current Treatment Options and Burden of Daily Care Seborrheic dermatitis is a chronic, inflammatory skin disease that affects more than 10 million people in the U.S. Survey found that, among adults with seborrheic dermatitis who use treatments, only ... CORRECTION: Nationwide Survey of People with Seborrheic Dermatitis Reveals Dissatisfaction with Current Treatment Options and Burden of Daily Care Nasdaq: ZORYVE® (roflumilast) Topical Foam, 0.3%, for the Treatment of Seborrheic Dermatitis Launches in the United States ZORYVE® (roflumilast) Topical Foam, 0.3%, for the Treatment of Seborrheic Dermatitis Launches in the United States Seeking Alpha: FDA Approves Arcutis’ ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older FDA Approves Arcutis’ ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older